AbbVie Valuation
Is ABBV * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ABBV * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ABBV * (MX$2880) is trading below our estimate of fair value (MX$4980.9)
Significantly Below Fair Value: ABBV * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ABBV *?
Other financial metrics that can be useful for relative valuation.
| What is ABBV *'s n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$282.63b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.1x |
| Enterprise Value/EBITDA | 12.5x |
| PEG Ratio | 2x |
Price to Earnings Ratio vs Peers
How does ABBV *'s PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 60.6x | ||
AMGN Amgen | 21.6x | 8.9% | US$144.8b |
REGN Regeneron Pharmaceuticals | 24.1x | 11.2% | US$95.3b |
GILD Gilead Sciences | 168.2x | 33.6% | US$81.6b |
VRTX Vertex Pharmaceuticals | 28.4x | 11.5% | US$102.7b |
ABBV * AbbVie | 61.5x | 23.4% | Mex$296.2b |
Price-To-Earnings vs Peers: ABBV * is expensive based on its Price-To-Earnings Ratio (61.5x) compared to the peer average (22.1x).
Price to Earnings Ratio vs Industry
How does ABBV *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Earnings vs Industry: ABBV * is expensive based on its Price-To-Earnings Ratio (61.5x) compared to the Global Biotechs industry average (29.9x).
Price to Earnings Ratio vs Fair Ratio
What is ABBV *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 47.5x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ABBV *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$2,880.00 | Mex$3,150.27 +9.4% | 6.1% | Mex$3,532.20 | Mex$2,760.60 | n/a | 26 |
| Apr ’25 | Mex$2,999.70 | Mex$3,063.32 +2.1% | 6.3% | Mex$3,431.75 | Mex$2,682.10 | n/a | 27 |
| Mar ’25 | Mex$3,046.96 | Mex$3,089.63 +1.4% | 7.2% | Mex$3,521.38 | Mex$2,615.40 | n/a | 26 |
| Feb ’25 | Mex$2,847.82 | Mex$2,969.48 +4.3% | 9.4% | Mex$3,530.61 | Mex$2,325.04 | n/a | 27 |
| Jan ’25 | Mex$2,612.90 | Mex$2,877.82 +10.1% | 10.6% | Mex$3,447.65 | Mex$2,161.22 | n/a | 28 |
| Dec ’24 | Mex$2,463.82 | Mex$2,877.92 +16.8% | 10.6% | Mex$3,456.60 | Mex$2,166.82 | n/a | 28 |
| Nov ’24 | Mex$2,549.98 | Mex$3,031.58 +18.9% | 10.7% | Mex$3,700.97 | Mex$2,274.74 | n/a | 27 |
| Oct ’24 | Mex$2,597.00 | Mex$2,927.75 +12.7% | 10.7% | Mex$3,598.82 | Mex$2,211.96 | n/a | 27 |
| Sep ’24 | Mex$2,470.00 | Mex$2,834.82 +14.8% | 10.7% | Mex$3,493.90 | Mex$2,147.47 | n/a | 27 |
| Aug ’24 | Mex$2,502.11 | Mex$2,748.56 +9.8% | 10.6% | Mex$3,352.96 | Mex$2,101.86 | n/a | 28 |
| Jul ’24 | Mex$2,280.00 | Mex$2,889.29 +26.7% | 11.3% | Mex$3,528.23 | Mex$2,106.41 | n/a | 25 |
| Jun ’24 | Mex$2,340.00 | Mex$2,889.29 +23.5% | 11.3% | Mex$3,528.23 | Mex$2,106.41 | n/a | 25 |
| May ’24 | Mex$2,705.00 | Mex$2,960.21 +9.4% | 10.7% | Mex$3,506.08 | Mex$2,157.59 | n/a | 25 |
| Apr ’24 | Mex$2,862.23 | Mex$2,956.42 +3.3% | 10.9% | Mex$3,604.48 | Mex$2,162.69 | Mex$2,999.70 | 24 |
| Mar ’24 | Mex$2,792.63 | Mex$2,984.10 +6.9% | 11.1% | Mex$3,659.68 | Mex$2,195.81 | Mex$3,046.96 | 25 |
| Feb ’24 | Mex$2,739.87 | Mex$3,054.97 +11.5% | 11.3% | Mex$3,765.90 | Mex$2,259.54 | Mex$2,847.82 | 25 |
| Jan ’24 | Mex$3,212.99 | Mex$3,153.61 -1.8% | 11.3% | Mex$3,953.78 | Mex$2,372.27 | Mex$2,612.90 | 25 |
| Dec ’23 | Mex$3,068.58 | Mex$3,072.30 +0.1% | 11.2% | Mex$3,882.74 | Mex$2,329.64 | Mex$2,463.82 | 24 |
| Nov ’23 | Mex$2,906.60 | Mex$3,109.05 +7.0% | 11.6% | Mex$3,962.88 | Mex$2,377.73 | Mex$2,549.98 | 23 |
| Oct ’23 | Mex$2,735.82 | Mex$3,183.55 +16.4% | 11.7% | Mex$4,027.70 | Mex$2,416.62 | Mex$2,597.00 | 23 |
| Sep ’23 | Mex$2,789.13 | Mex$3,199.83 +14.7% | 11.3% | Mex$4,037.20 | Mex$2,523.25 | Mex$2,470.00 | 23 |
| Aug ’23 | Mex$2,845.00 | Mex$3,260.75 +14.6% | 10.9% | Mex$4,074.78 | Mex$2,546.74 | Mex$2,502.11 | 22 |
| Jul ’23 | Mex$3,095.71 | Mex$3,248.67 +4.9% | 10.8% | Mex$4,006.40 | Mex$2,504.00 | Mex$2,280.00 | 23 |
| Jun ’23 | Mex$2,861.00 | Mex$3,212.88 +12.3% | 11.0% | Mex$3,920.14 | Mex$2,450.09 | Mex$2,340.00 | 24 |
| May ’23 | Mex$2,974.01 | Mex$3,326.17 +11.8% | 11.9% | Mex$3,918.47 | Mex$2,326.59 | Mex$2,705.00 | 23 |
| Apr ’23 | Mex$3,196.00 | Mex$3,068.15 -4.0% | 11.6% | Mex$3,574.04 | Mex$2,263.56 | Mex$2,862.23 | 23 |
Analyst Forecast: Target price is less than 20% higher than the current share price.